Market Access Jazz and Lilly cancer drugs cleared for use by NHS PharmaphorumJazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.Market AccessOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Jazz’s biliary tract cancer drug Ziihera and Lilly’s Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance. Market AccessOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain GroundNext: Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls Related Stories Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026 Market Access UK, pharma industry pilot rapid access routes for medicines pharminent July 5, 2026 Market Access Medicare GLP-1 Bridge Launches July 1 With $50 Copays pharminent July 3, 2026
